Yahoo · Oct 5, 2026
Surrozen secures FDA clearance for SZN-8141 clinical trial
Surrozen intends to dose the first patient in its DUET clinical trial during the fourth quarter of 2026.
SR
NASDAQ · SRZN
Surrozen, Inc.
Healthcare · Biotechnology
$25.15
Up+$2.83 (+11.23%)
Updated Oct 9, 2026, 12:24 AM
SID Score
6.2/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 201.6M
- P/E ratio
- -12.03
- Dividend yield
- 0.00%
- 52-week range
- $11.39 – $37.83
- Volume
- 416.49K
- Avg. volume
- 63.79K
Price performance · SRZN
SRZN price history
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 7, 2026
SRZN closed at $25.15 after 20 trading sessions, up 29.28% for the selected period.
- Last close
- $25.15
- Period change
- +29.28%
- Period low
- $16.16
- Period high
- $33.68
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 7, 2026 | $25.81 | $26.21 | $25.08 | $25.145 | 416.49K |
| Oct 6, 2026 | $29.26 | $29.26 | $26.1801 | $26.37 | 603.82K |
| Oct 5, 2026 | $29.32 | $29.70 | $26.97 | $29.13 | 439.18K |
| Oct 2, 2026 | $30.57 | $30.68 | $28.93 | $29.32 | 646.04K |
| Oct 1, 2026 | $31.60 | $32.00 | $29.72 | $30.00 | 438.53K |
| Sep 30, 2026 | $32.155 | $33.38 | $30.975 | $32.18 | 1.66M |
| Sep 29, 2026 | $29.83 | $32.545 | $29.50 | $31.98 | 558.12K |
| Sep 28, 2026 | $29.71 | $30.39 | $29.01 | $29.64 | 409.76K |
| Sep 25, 2026 | $34.72 | $37.83 | $28.55 | $29.54 | 1.93M |
| Sep 24, 2026 | $30.56 | $35.86 | $29.10 | $33.68 | 11.53M |
| Sep 23, 2026 | $17.54 | $17.54 | $16.14 | $16.16 | 115.54K |
| Sep 22, 2026 | $16.78 | $17.60 | $16.56 | $17.60 | 89.81K |
| Sep 21, 2026 | $16.74 | $17.45 | $16.44 | $16.53 | 129.01K |
| Sep 18, 2026 | $16.97 | $17.68 | $16.43 | $16.55 | 190.17K |
| Sep 17, 2026 | $17.27 | $17.475 | $16.44 | $16.94 | 268.46K |
| Sep 16, 2026 | $17.84 | $17.86 | $16.78 | $16.93 | 116.74K |
| Sep 15, 2026 | $17.81 | $18.34 | $17.15 | $17.77 | 151.94K |
| Sep 14, 2026 | $19.03 | $19.29 | $17.61 | $17.84 | 198.2K |
| Sep 11, 2026 | $19.68 | $19.72 | $18.71 | $19.00 | 145.34K |
| Sep 10, 2026 | $19.95 | $20.15 | $18.995 | $19.45 | 277.75K |
Latest SRZN news
The latest Smart Investors Daily articles mentioning SRZN.
Stock researchCompany · Overview
Company
Market Activity
Research & News
SRZN research
Overview
Company profile and research snapshot.
Company profile
Surrozen Inc is a clinical-stage biotechnology company committed to discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. Its product candidate includes SZN-1326 (Fzd5/Lrp6, SWAP), SZN-413 and SZN-043 (E3/ASGR1, SWEETS).
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $38.50
- Implied upside
- —
- Analysts
- 8
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 25, 2026 | HC Wainwright & Co. | Buy | — |
| Aug 20, 2026 | William Blair | Outperform | — |
| Aug 10, 2026 | HC Wainwright & Co. | Buy | — |
| May 7, 2026 | HC Wainwright & Co. | Buy | — |
| Apr 21, 2026 | TD Cowen | Buy | — |
News briefing
No generated briefing is available yet.
Yahoo · Oct 2, 2026
Surrozen Announces FDA Clearance of IND Application for SZN-8141 for the Treatment of Diabetic Macular Edema
First patient expected to be dosed in the DUET study in the fourth quarter of 2026 Milestone triggers second closing of March 2025 private placement expected to provide approximately $95.1M in gross proceeds SOUTH SAN FRANCISCO, Calif., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Surrozen, Inc. (Surrozen or the Company) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics to harness the power of Wnt signaling to address the underlying drivers of disease in sight-threatening ophthalmic
ChartMill · Sep 25, 2026
Unusual volume stocks are being observed in Friday's session.
Unusual volume stocks are being observed in Friday's session.
Benzinga · Sep 25, 2026
HC Wainwright & Co. Maintains Buy on Surrozen, Raises Price Target to $54
HC Wainwright & Co. analyst Matthew Caufield maintains Surrozen (NASDAQ:SRZN) with a Buy and raises the price target from $44 to $54.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
